Preparation and characterization of carvedilol-loaded poly(d,l) lactide nanoparticles/microparticles as a sustained-release system
Source abstract
Abstract
Carvedilol poly(d,l)-lactide nanoparticles/microparticles were prepared. The size and morphology of the developed particles were optimized to study the carvedilol release profile by studying the effect of organic solvents and polymer amount through atomic force microscopy analysis. Spherical particles were obtained with a minimum size of 125 nm in the case of acetone and a maximum size of 970 nm in the case of dichloromethane affording microparticles formation. The interaction was confirmed by differential scanning calorimeter and Fourier transform infrared. The in vitro release profile of the multicompartment system (pure carvedilol, loaded nanoparticles and microparticles) has shown a sustained release with Korsmeyer–Peppas with T lag model.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Polymer Surface Interaction Studies · Advanced Drug Delivery Systems · Hydrogels: synthesis, properties, applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmacy, Faculty of Medicine and Health Sciences, An Najah National University, Nablus, Palestine
The Nanotechnology Research Laboratory, Materials Engineering Department, Al-Quds University, East Jerusalem, Palestine
Chemical Engineering Department, Faculty of Engineering, An Najah National University, Nablus, Palestine
References (53)
Show source-provided references
1. 10.1007/BF0321835510.1007/BF03218355 ↗
2. 10.1039/C0SM00862A10.1039/C0SM00862A ↗
3. 10.1007/s13233-013-1025-610.1007/s13233-013-1025-6 ↗
4. 10.1007/BF0321896310.1007/BF03218963 ↗
5. 10.1080/00914037.2013.76922710.1080/00914037.2013.769227 ↗
6. 10.1016/S0168-3659(00)00339-410.1016/S0168-3659(00)00339-4 ↗
7. 10.2217/17435889.3.3.30510.2217/17435889.3.3.305 ↗
8. 10.2147/IJN.S996210.2147/IJN.S9962 ↗
9. 10.1080/0091403980804106210.1080/00914039808041062 ↗
10. 10.1023/A:102150972229610.1023/A:1021509722296 ↗
11. 10.1002/mabi.20060010110.1002/mabi.200600101 ↗
12. 10.1016/0378-5173(89)90281-010.1016/0378-5173(89)90281-0 ↗
13. 10.1081/DDC-10010219710.1081/DDC-100102197 ↗
14. 10.1016/j.progpolymsci.2011.01.00110.1016/j.progpolymsci.2011.01.001 ↗
15. 10.1007/BF0140947110.1007/BF01409471 ↗
16. 10.1016/S0169-409X(00)00130-710.1016/S0169-409X(00)00130-7 ↗
17. 10.2174/15672010777931478510.2174/156720107779314785 ↗
18. 10.2165/00129784-200808040-0000710.2165/00129784-200808040-00007 ↗
19. 10.1016/j.cardfail.2008.12.01010.1016/j.cardfail.2008.12.010 ↗
20. 10.2174/13892002113140010510.2174/138920021131400105 ↗
21. 10.1021/cm402261310.1021/cm4022613 ↗
22. 10.3109/10837450.2013.81901110.3109/10837450.2013.819011 ↗
23. 10.1007/s13233-010-0801-910.1007/s13233-010-0801-9 ↗
24. 10.1007/BF0321856810.1007/BF03218568 ↗
25. 10.1016/S0962-8924(98)01415-910.1016/S0962-8924(98)01415-9 ↗
26. 10.1111/j.1468-2494.2009.00462_4.x10.1111/j.1468-2494.2009.00462_4.x ↗
27. 10.1007/s13233-012-0005-610.1007/s13233-012-0005-6 ↗
28. 10.1063/1.243241010.1063/1.2432410 ↗
29. U.S. Food and Drug Administration. Dissolution methods. Accessed at: http://www.accessdata.fda.gov/scripts/cder/dissolution/dsp_getallData.cfm
30. 10.1208/s12248-010-9185-110.1208/s12248-010-9185-1 ↗
31. 10.1002/jps.260084081610.1002/jps.2600840816 ↗
32. 10.1002/jbm.a.3044310.1002/jbm.a.30443 ↗
33. 10.1016/S0928-0987(01)00095-110.1016/S0928-0987(01)00095-1 ↗
34. 10.1016/S0378-5173(00)00407-510.1016/S0378-5173(00)00407-5 ↗
35. 10.1016/0378-5173(94)90260-710.1016/0378-5173(94)90260-7 ↗
36. 10.1016/0168-3659(87)90035-610.1016/0168-3659(87)90035-6 ↗
37. 10.1016/0168-3659(87)90034-410.1016/0168-3659(87)90034-4 ↗
38. 10.1016/0169-409X(95)00022-Y10.1016/0169-409X(95)00022-Y ↗
39. 10.1016/j.ejpb.2010.11.00110.1016/j.ejpb.2010.11.001 ↗
40. 10.1016/j.memsci.2008.08.03910.1016/j.memsci.2008.08.039 ↗
41. 10.1016/j.memsci.2007.11.02910.1016/j.memsci.2007.11.029 ↗
42. 10.1016/0378-5173(96)04618-210.1016/0378-5173(96)04618-2 ↗
43. 10.1021/js950164r10.1021/js950164r ↗
44. 10.1016/S0939-6411(01)00130-810.1016/S0939-6411(01)00130-8 ↗
45. 10.1016/0142-9612(95)93258-F10.1016/0142-9612(95)93258-F ↗
46. 10.1016/j.biomaterials.2003.12.03210.1016/j.biomaterials.2003.12.032 ↗
47. 10.1016/j.jconrel.2003.12.02110.1016/j.jconrel.2003.12.021 ↗
48. 10.1016/S0168-3659(99)00012-710.1016/S0168-3659(99)00012-7 ↗
49. 10.1590/S0100-4042200300050001710.1590/S0100-40422003000500017 ↗
50. Motulsky H. J. · 2003
51. Korsmeyer, R. W.; Peppas, N. A. Macromolecular and Modeling Aspects of Swelling Controlled Systems; Marcel Dekker Inc.: New York, 1983; pp. 77–89.
52. 10.1016/0378-5173(94)00324-X10.1016/0378-5173(94)00324-X ↗
53. Aulton M. · 2007